Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers

Myocardial Fibrosis Clinical Trial

Official title:

Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02834104
• Other study ID #: 2011-30
• Secondary ID: 2011-A01395-36
• Status: Completed
• Phase: N/A
• Start date: November 18, 2014
• Est. completion date: October 27, 2022

Study information

• Verified date: November 2022
• Source: Assistance Publique Hopitaux De Marseille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive fibrosis is increasingly recognized in a variety of conditions despite the absence of ischemia. Regardless of the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction. This dysfunction may present clinically with symptoms of cardiac failure although this is often a subclinical disease. Various imaging modalities and collagen biomarkers have been used as surrogate markers to assess the presence, extent, and turnover of myocardial fibrosis. Techniques using echocardiography, cardiac magnetic resonance, and nuclear imaging have been developed to detect early features of systolic and diastolic left ventricular dysfunction and impaired contractile reserve. Further identification of diffuse reactive fibrosis may be possible with evolving cardiac magnetic resonance and molecular techniques. The goal of this protocol is to validate cardiac magnetic resonance imaging as a new tool for fibrosis quantification against histology as standard of reference.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: October 27, 2022
• Est. primary completion date: December 19, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients who require surgical aortic valve replacement , which will benefit from an MRI to measure fibrosis in the months preceding the surgery.

• Patient submitted to the social security scheme

• Patient agreeing to participate in the study and who signed the informed consent.

Exclusion Criteria:

• A history of myocardial

• Unstable Patients requiring treatment with catecholamines.

• hepatocellular insufficiency of alcoholic origin

• Severe renal impairment

• Appearance before examining coronary syndrome at high risk, defined according to international recommendations.

• History of known allergy to gadolinium at diagnosis

• Pregnant or lactating

• Patient < 18 years

Related Conditions & MeSH terms

• Fibrosis
• Myocardial Fibrosis

Intervention

Device:
• RMI

Other:
• myocardial biopsy

Biological:
• blood sample

Locations

Country	Name	City	State
France	Assistance Publique Hopitaux de Marseille	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	quantification of myocardial fibrosis by RMI		5years
Secondary	measuring biomarkers of fibrosis	BLOOD SAMPLE	5 years